This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Peregrine Pharma: Cash Crisis and Exaggerated Survival Benefit

Peregrine took none of these precautions. Seventy-nine patients were enrolled in the two bavituximab arms but only 40 patients were accounted for in the survival analysis. That means 39 bavituximab patients, or 49%, were censored and excluded from the analysis.

Censored patients show up as "tick marks" on the bavituximab Kaplan-Meier survival curves seen in the slide below.

To put Peregrine's 49% patient censoring rate in perspective, six phase III lung cancer studies published recently in the medical literature had an average censoring rate of 19%. On average, each of these studies enrolled 710 patients.

Peregrine's bavituximab study enrolled just 117 patients (including the 38 patients in the control arm) but had more than double the rate of censoring. That speaks to very poor trial conduct.

The amount of patient censoring is important but so is the time at which censoring occurs. In well-conducted clinical trials, more censoring occurs after median overall survival is reached. This typically reflects patients who remain alive in the study when the analysis was conducted. If or when these late-censored patients die, the median overall survival estimate of the trial will not change appreciably. Remember, median is the value in the middle, not the average.

In the Peregrine study, however, much more patient censoring occurred before median overall survival was reached. You can count the tick marks on the survival curves. As a result, the median overall survival estimate is skewed higher artificially. If any of these early-censored patients are found to have died, the median overall survival of pooled bavituximab will not be 12 months but could be significantly lower.

The problem with early censoring can be seen most clearly in the study's 3 mg bavituximab arm, where the median overall survival was reported to be 13 months. However, this analysis was based on 15 deaths, while 18 patients were censored before the median survival was reached. When more patients are missing than confirmed dead in a survival analysis, the estimate is entirely unreliable.

Early censoring can be justified if a trial is relatively immature, meaning patients haven't been followed long enough to analyze.

That's not the case with the Peregrine trial. The bavituximab study was unblinded in December 2011. When the survival data were presented on Sept. 7, the company had 9 months of follow up at a minimum (and this assumes that all patients enrolled on the last day of the trial, which obviously didn't happen.)

Peregrine hasn't disclosed the reasons why patients were censored and the company did not return a phone call seeking comment. But based on previous statements, the bavituximab study was mature enough to avoid early censoring of patients for too-short follow up.

That leaves just one possibility: All the patients censored early in the study before nine months -- and there are lots of them -- were lost to follow up.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,265.99 +109.14 0.64%
S&P 500 2,011.36 +9.79 0.49%
NASDAQ 4,593.4250 +31.2360 0.68%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs